CTOs on the Move

Rare Cancer Research Foundation

www.rarecancer.org

 
The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that catalyze effective research and accelerate deployment of promising therapies. While rare cancers accounted for just over 25 percent of all new cancer diagnoses in 2013, they comprised more than 40 percent of all cancer deaths. RCRF`s goal is to develop research infrastructure for each rare cancer.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.rarecancer.org
  • 112 S. Duke Street Suite 101
    Durham, NC USA 27701
  • Phone: 919.827.8373

Executives

Name Title Contact Details

Similar Companies

Advanced Solutions

Advanced Solutions designs and manufactures biofabrication systems for next-generation drug discovery, personalized medicine, and regenerative therapeutics.

BioStudio Visual Communications

BioStudio Visual Communications is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GrowBLOX Sciences

GrowBLOX Sciences (OTCQ GBLX) – merges state-of-the-art technologies in plant biology, cultivation and post-production processes in order to optimize safe, consistent medical Cannabis. The company is pioneering technologies and industry-leading processes in combination with a Big Data-driven clinical research and development program to bring relief to patients in communities across the country.

WHPM Biotech

WHPM Biotech is a Irwindale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.